Nordihydroguaiaretic Acid for Health & Longevity

Evidence Review created on 09/10/2026 using AI4L / Opus 5

Also known as: NDGA, Masoprocol, meso-NDGA, Actinex, Larreastat

Motivation

Nordihydroguaiaretic acid, usually shortened to NDGA, is a plant compound that forms much of the sticky resin coating the leaves of the creosote bush, a shrub of the deserts of the American Southwest and northern Mexico. It is a powerful antioxidant, and for roughly two decades in the middle of the twentieth century it was added to fats and oils to keep them from turning rancid.

Desert peoples brewed the same leaves as a tea, later sold widely as chaparral. The compound was removed from the food supply after animal feeding studies raised kidney concerns, and reports of severe liver injury followed its later career as an herbal product. Yet it is also one of a small number of compounds that lengthened the lives of male mice in a long-running government animal programme, which returned it to the attention of people interested in slowing aging.

This review examines what is known about nordihydroguaiaretic acid: how it acts in the body, what human and animal work shows about benefit, what the liver and kidney safety record contains, how it has been dosed, and how its effects can be tracked.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Masoprocol

Covers the compound under its drug name, setting out its origin in the creosote bush, its status as the meso isomer of nordihydroguaiaretic acid, and its antioxidant and antineoplastic properties.

Examine

No Examine article exists for nordihydroguaiaretic acid. Examine indexes dietary supplements with human trial data, and this compound’s only regulated form was a prescription topical cream, a category the site does not typically cover.

ConsumerLab

No ConsumerLab article exists for nordihydroguaiaretic acid. ConsumerLab tests marketed supplement categories, and no sold category is standardised to this compound; its only regulated form was a prescription cream, which ConsumerLab does not cover.

Systematic Reviews

The systematic reviews below address the compound’s anti-inflammatory mechanism, the liver-injury signal attached to the plant it comes from, and the graded evidence for chaparral as a whole.

Targeting Mammalian 5-Lipoxygenase by Dietary Phenolics as an Anti-Inflammatory Mechanism: A Systematic Review - Giménez-Bastida et al., 2021

Confirms the compound blocks 5-lipoxygenase (an enzyme that builds inflammatory signalling molecules) in cells, while judging human evidence for this pathway inconclusive.
Herb-induced liver injury: Systematic review and meta-analysis - Ballotin et al., 2021

Pools 936 cases across 79 botanicals, lists chaparral among the most frequently implicated, and reports recovery, transplant and death rates for the set.
Chaparral monograph:a clinical decision support tool - Ulbricht et al., 2003

Grades the evidence behind every claimed chaparral indication and compiles dosing, kinetics, interactions and adverse effects into a single appraisal.

Both sides of the trade-off are represented: the anti-inflammatory mechanism by Giménez-Bastida and colleagues, the principal risk by Ballotin and colleagues. No systematic review or meta-analysis addresses lifespan or healthspan outcomes for this compound, because no human longevity trial exists to pool.

Mechanism of Action

Nordihydroguaiaretic acid is a catechol lignan: two rings, each carrying adjacent hydroxyl groups that donate electrons. That chemistry drives most of its actions. It quenches free radicals, and it blocks lipoxygenases — the enzymes that convert arachidonic acid, a fatty acid from cell membranes, into leukotrienes, signalling molecules that recruit inflammatory cells. It inhibits 5-lipoxygenase most potently but not selectively, also hitting the 12- and 15-lipoxygenases.

Beyond that pathway, it inhibits two growth receptors, the insulin-like growth factor 1 receptor (IGF-1R, which relays growth signals) and HER2 (a related receptor amplified in some breast cancers), at micromolar concentrations (Youngren et al., 2005). It also inhibits p300, an enzyme that attaches acetyl groups to histones, the proteins DNA winds around; less acetylation at H3K27 (a site on histone H3) releases a brake on autophagy, the cell’s recycling process (Tezil et al., 2019).

Two readings compete. The protective one credits radical scavenging and leukotriene suppression. The damaging one notes that the same catechol autoxidises to a reactive ortho-quinone forming glutathione adducts, so the molecule acts as a pro-oxidant under some conditions (Billinsky et al., 2007).

Pharmacologically, it resists oxidative phase I metabolism and is cleared mainly by hepatic glucuronidation (sugar groups attached to aid excretion), while inhibiting the drug-metabolising enzymes CYP1A2, CYP2C9, CYP2D6 and CYP3A4 (Jeong et al., 2017). No human elimination half-life has been published; oral exposure plateaus rather than rising with dose, and tissue penetration is documented only as tumour-to-plasma ratios in brain tumours (Ahluwalia et al., 2024).

Historical Context & Evolution

An ethnopharmacological review documents Indigenous peoples of the Sonoran and Chihuahuan deserts preparing creosote bush leaves as teas and poultices for complaints from colds and rheumatic pain to gallstones and infertility (Arteaga et al., 2005). Industrial interest followed a different route: from the 1940s the isolated compound was used as an antioxidant preservative in fats, oils and fibres, and it sat on the United States list of substances generally recognised as safe.

That status ended after feeding studies in rats found dose-dependent kidney lesions. Grice and colleagues described stunted growth and organ damage (Grice et al., 1968), and a companion paper documented the lesion — fluid-filled cysts in the kidney tubules — under light and electron microscopy (Goodman et al., 1970). Later work traced it to obstruction of individual nephrons, the kidney’s filtering units (Evan & Gardner, 1979). The compound left food use.

It returned twice. As chaparral it was promoted from the 1960s as an anticancer tea, until a cluster of hepatitis reports prompted a 1992 Food and Drug Administration advisory and a voluntary withdrawal organised by the herbal trade association, whose members derive their revenue from selling such products. Separately, a 10% cream was approved in 1992 for sun-induced skin lesions, then withdrawn from the market in 1996. Interest revived again in 2008, when the compound extended male mouse lifespan in a federal testing programme, and pharmaceutical work shifted to methylated derivatives designed to keep the activity without the reactive catechol.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every candidate outcome rests either on a single small human trial or on animal and cell work, so no clinical endpoint or validated human surrogate has been replicated across more than one trial.

Medium 🟩 🟩

Clearance of Actinic Keratoses with the Topical Form

Applied to sun-damaged facial and scalp skin, the 10% cream reduced the count of actinic keratoses (rough, scaly precancerous patches caused by cumulative sun exposure). The proposed basis is inhibition of lipoxygenase signalling together with suppressed keratinocyte proliferation. The evidence is one double-blind, vehicle-controlled, multicentre randomised controlled trial in 113 treated participants. Skin irritation was common but did not track with response, and because the product left the market in 1996 no modern replication exists.

Magnitude: Median lesion count fell 71.4% from baseline versus 4.3% with vehicle; mean count fell from 15.0 to 5.4 lesions (Olsen et al., 1991).

Low 🟩

Slowed Rise of Prostate-Specific Antigen in Recurrent Prostate Cancer

Oral dosing lengthened the doubling time of prostate-specific antigen (PSA, a protein released by prostate tissue and tracked as a marker of tumour activity) in men with rising PSA after local treatment. Evidence is one single-arm phase 2 trial stopped early, with no control group.

Magnitude: Median doubling time lengthened by 1.4 months (range −6.1 to +19.8); seven of twelve men had non-sustained PSA declines of 1.9–15.8% (Friedlander et al., 2012).

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

Male mice gained 8–10% lifespan in replicated federal testing (Strong et al., 2016); females gained none. An independent replication found more fatal tumours (Spindler et al., 2015). Net reading: animal data only, unproven in people.

Lower Blood Triglycerides and Liver Fat

Rats on high-fructose diets showed lower triglycerides and less liver fat, with matching shifts in lipid-handling genes (Zhang et al., 2015). No human metabolic trial exists; the basis is animal work only.

Lowered Blood Glucose in Rodent Models of Type 2 Diabetes

Oral dosing lowered plasma glucose in diabetic mice without raising insulin (Luo et al., 1998), and cut glucose 35% in fat-fed diabetic rats, matching metformin (Reed et al., 1999). Animal data only.

Damped Leukotriene-Driven Inflammation

Cell and tissue work shows potent suppression of 5-lipoxygenase products, the basis for its long use as a laboratory inhibitor. A systematic review found human evidence for this pathway inconclusive (Giménez-Bastida et al., 2021).

Neuroprotection in an Animal Model of Motor Neurone Disease

Mice carrying a disease-causing gene survived longer, with reduced inflammatory activation of microglia, the brain’s resident immune cells. Basis is animal only; no human neurological outcome measured (West et al., 2004).

Antiviral and Antimicrobial Activity in Laboratory Assays

Laboratory assays report activity against several viruses (Villalobos-Sánchez et al., 2023) and against bacterial biofilm formation (Visser et al., 2023), at concentrations exceeding human plasma levels. Basis is in-vitro only.

Benefit-Modifying Factors

Catechol-clearing genotypes: Clearance runs through glucuronidation by UGT enzymes (which attach sugar groups to make compounds water-soluble) and through COMT (which caps catechols with a methyl group). Fast-clearing variants plausibly lower tissue exposure, though no human study has tested this.
Baseline inflammatory load: Lipoxygenase blockade has more room to act when leukotriene-driven inflammation is high. Individuals already at low inflammatory markers have less headroom for measurable change, a pattern common to anti-inflammatory agents.
Sex: In replicated mouse work the lifespan gain appeared only in males, and matching blood levels in females did not produce it, implying a sex-linked response rather than a dosing artefact (Strong et al., 2016).
Baseline liver function: Hepatic glucuronidation is the main clearance route, so reduced liver function raises exposure for a given dose, shifting the balance from any benefit toward the toxicity seen at higher concentrations.
Pre-existing conditions: Benefit signals are indication-specific — sun-damaged skin for the topical form, rising tumour markers for oral use. Neither transfers to individuals without those conditions, and no benefit has been shown in healthy adults.
Age: Mouse dosing began in mid-life, so the animal data speak to mid-life onset. For adults at the older end of the target range, declining liver and kidney reserve narrows the gap between an active and a toxic exposure.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the liver and kidney signals rest on spontaneous case reports, a regulatory case series and rodent feeding studies, none of which is a controlled trial, so no adverse event has been documented across more than one trial.

Medium 🟥 🟥

Drug-Induced Liver Injury

Prolonged oral intake of the parent plant has produced jaundice with markedly raised liver chemistries, typically in a cholestatic pattern in which bile flow is impaired. Onset ranged from three to fifty-two weeks and most cases resolved after intake stopped, but a minority progressed. A pooled analysis of botanical liver injury lists chaparral among the most frequently implicated products (Ballotin et al., 2021). Severity is the dominant safety concern for any oral use of this compound.

Magnitude: Of 18 adverse-event reports to the Food and Drug Administration, 13 showed hepatotoxicity; four progressed to cirrhosis and two required liver transplantation (Sheikh et al., 1997).

Contact Dermatitis and Local Irritation from the Topical Form

The cream caused redness and flaking in most treated participants, and dermatology reports afterwards identified it as a strong sensitiser capable of producing true allergic contact dermatitis (an immune-mediated rash on re-exposure) rather than simple irritation. This reaction, not lack of efficacy, is the reason usually given for the product’s commercial withdrawal. The reaction is local and reversible after discontinuation.

Magnitude: Irritation occurred in 61.5% of treated participants versus 26.7% on vehicle in the pivotal trial (Olsen et al., 1991); sensitisation was reported separately (Epstein, 1994).

Gastrointestinal and Neurologic Adverse Events at Gram-Level Oral Doses

At 2000 mg daily, oral dosing produced nausea and vomiting severe enough to cause dehydration, and one instance of cognitive disturbance. Events were graded rather than counted as rates, and the trial population was small and elderly, so the frequency in healthy adults is unknown. Derivative work at higher oral doses was tolerated but achieved little systemic exposure, which limits what those doses say about the parent compound.

Magnitude: In twelve men dosed at 2000 mg daily, single grade 3 events of nausea with vomiting, dehydration-related syncope (fainting) and cognitive disturbance were recorded (Friedlander et al., 2012).

Low 🟥

Cystic Kidney Disease

Sustained oral exposure produces fluid-filled kidney cysts in rats by obstructing individual nephrons. One person developed acquired cystic kidney disease and a cystic kidney cancer after years of chaparral tea (Smith et al., 1994). Human evidence is a single uncontrolled report.

Magnitude: The direction is toward cyst formation with sustained oral exposure, reproducible in rats at dietary doses; the literature reports no incidence figure in humans, only the single case (Goodman et al., 1970).

Speculative 🟨

Increased Tumour Burden and Bleeding ⚠️ Conflicted

Mice fed the compound lived longer yet died with more liver, lung and thymus tumours and abdominal bleeding, findings absent from federal testing. Rodent data only; net reading: an unresolved signal against assuming safety.

Reactive Quinone Formation

The catechol autoxidises to an ortho-quinone that binds glutathione and other cellular proteins. This is the leading chemical explanation for the organ toxicity, but it is demonstrated in chemical and microsomal systems only.

Risk-Modifying Factors

Drug-metabolising genotypes: Variants of CYP2C9 (a liver enzyme handling warfarin and phenytoin) and CYP1A2 alter how much co-administered drug accumulates when this compound inhibits them; poor-metaboliser genotypes widen that effect.
Baseline liver chemistry: Raised transaminases (enzymes released by damaged liver cells) or bilirubin before starting indicate reduced hepatic reserve, and the reported injuries were hepatic. A normal baseline also provides the comparison against which later drift is judged.
Sex: Human safety data are too sparse to establish sex differences. The one replicated sex effect is in mice, where only males gained lifespan, so female rodents carried exposure without the offsetting benefit.
Pre-existing conditions: Chronic liver disease, biliary disease, polycystic kidney disease and reduced kidney filtration all overlap directly with the documented target organs, compounding an injury that would otherwise be subclinical.
Age: Hepatic glucuronidation capacity and kidney filtration both decline with age, raising exposure per dose. Older adults also carry more concurrent medication, multiplying the interaction surface described below.
Concurrent hepatotoxic exposure: Alcohol, high-dose acetaminophen and botanical products with their own liver signals are additive with the compound’s hepatic risk, and were present in several reported cases of chaparral-associated injury.

Key Interactions & Contraindications

CYP2C9 substrates (warfarin, phenytoin, glipizide): Caution. Enzyme inhibition raises substrate levels, risking bleeding or toxicity. Mitigation is separation from these agents, or intensified monitoring of the international normalised ratio and drug levels.
CYP3A4 substrates (tacrolimus, cyclosporine, simvastatin, midazolam): Caution. Inhibition raises exposure, with rhabdomyolysis (muscle breakdown releasing protein into the blood) or excess sedation as consequences. Mitigation is dose reduction of the substrate with level monitoring.
CYP1A2 and CYP2D6 substrates (theophylline, tizanidine, metoprolol, codeine): Caution. Inhibition raises exposure to theophylline and tizanidine and lowers activation of codeine. Consequence is toxicity or analgesic failure; mitigation is choosing alternative agents.
Other hepatotoxic prescription drugs (methotrexate, isoniazid, amiodarone): Absolute contraindication in combination. Consequence is additive liver injury on an organ already the compound’s main target; no dose adjustment reliably offsets it.
Acetaminophen and other over-the-counter analgesics: Caution. Acetaminophen adds hepatic burden through glutathione depletion, which the compound’s reactive quinone also consumes. Mitigation is capping acetaminophen well below 3 g daily.
Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen): Monitor. Blocking cyclooxygenase alongside lipoxygenase shifts arachidonic acid handling and adds gastric irritation. Mitigation is separating dosing and using the shortest analgesic course.
Anticoagulants and antiplatelets (warfarin, apixaban, aspirin, clopidogrel): Caution. Bleeding was seen in long-term rodent dosing, and glioma trial protocols excluded anticoagulated participants outright. Mitigation is avoiding the combination.
Supplements with liver signals (green tea extract, kava, garcinia, comfrey): Caution. Each appears in the same pooled analysis of botanical liver injury (Ballotin et al., 2021), so the combination stacks independent hepatic risks. Mitigation is not combining them.
Supplements with additive lipoxygenase or anti-inflammatory action (boswellia, curcumin, fish oil): Monitor. Effects on leukotriene and eicosanoid signalling are additive, and fish oil adds antiplatelet effect. Mitigation is staggered introduction so any reaction is attributable.
Alcohol and other interventions: Caution. Regular alcohol intake induces hepatic stress and was a co-exposure in reported chaparral cases. Mitigation is abstaining for the duration of any oral course.

Populations who should avoid Nordihydroguaiaretic Acid:

Anyone with chronic liver disease, including Child-Pugh Class B or C cirrhosis, or with baseline alanine aminotransferase above twice the upper limit of normal
Anyone with a prior episode of drug-induced or herb-induced liver injury
Anyone with reduced kidney filtration (estimated glomerular filtration rate below 60 mL/min/1.73 m²), polycystic kidney disease or a solitary kidney
Anyone taking narrow-therapeutic-index drugs cleared by CYP2C9 or CYP3A4, or taking any anticoagulant
Anyone pregnant or breastfeeding, given the absence of reproductive safety data
Anyone with prior allergic contact dermatitis to the topical form

Risk Mitigation Strategies

Baseline liver panel before any oral use: Alanine aminotransferase (ALT, a liver enzyme released when liver cells are damaged), aspartate aminotransferase, alkaline phosphatase and bilirubin establish the comparison against which drug-induced liver injury is detected.
Scheduled liver retesting: Repeating the panel at 4 weeks, 8 weeks and then quarterly matches the 3-to-52-week onset window of reported chaparral hepatitis, catching a rise before jaundice appears.
Predefined stop rule: Discontinuing at ALT above three times the upper limit of normal, or at any bilirubin rise, is the threshold at which reported cases resolved on withdrawal rather than progressing to cirrhosis.
Time-limited courses rather than continuous intake: Confining oral use to defined blocks of 4 to 8 weeks limits cumulative exposure, since every reported liver and kidney injury followed months to years of uninterrupted intake.
Kidney surveillance: Annual estimated glomerular filtration rate with urinalysis, plus renal ultrasound if intake extends beyond a year, targets the cyst formation that is the reproducible rodent lesion.
Alcohol and hepatotoxin avoidance: Abstaining from alcohol and from other liver-stressing supplements during a course removes the additive hepatic burden present in several reported chaparral injury cases.
Patch testing before topical use: Applying the cream to a small area for several days first identifies the allergic contact dermatitis that affected a large minority of users before it spreads across treated skin.
Medication reconciliation before starting: Reviewing every prescription against the CYP1A2, CYP2C9, CYP2D6 and CYP3A4 inhibition profile prevents the accumulation of narrow-therapeutic-index drugs such as warfarin and tacrolimus.

Therapeutic Protocol

No established longevity protocol: No human dosing regimen exists for healthspan or lifespan purposes. Every regimen below comes from an oncology, dermatology or traditional context, and none was designed to test aging outcomes.
Historical topical regimen: The withdrawn 10% cream was applied twice daily to affected skin for 14 to 28 days, with response assessed a month after the final application (Olsen et al., 1991).
Oral regimen used in oncology research: 2000 mg administered orally each day in three divided doses, continued in 28-day cycles until progression or toxicity, is the only published oral human regimen (Friedlander et al., 2012).
Traditional chaparral preparation: Herbal practice steeps roughly 1 to 2 g of dried leaf as a tea. Content of the active lignan varies widely between products, so delivered dose is not controlled.
Competing approaches: Herbal practice uses the whole-plant preparation for its combined constituents; pharmaceutical development instead uses methylated derivatives, on the argument that removing the reactive catechol removes the organ toxicity.
Who advanced each approach: The derivative route was developed by Ru Chih Huang’s group at Johns Hopkins with Erimos Pharmaceuticals, which funded the resulting trials; the whole-plant route descends from Sonoran and Chihuahuan desert traditional practice.
Time of day: No chronobiological data exist. Derivative dosing was once daily without a specified time, and fasted and fed administration of that derivative gave comparable exposure (Ahluwalia et al., 2024).
Half-life: No human elimination half-life has been published. Clearance is by hepatic glucuronidation, and oral exposure plateaus rather than rising with dose, which frustrates conventional accumulation estimates.
Single versus split dosing: The one published oral protocol split the 2000 mg daily dose into three administrations. Absent half-life data, neither that schedule nor a single daily dose can be justified pharmacokinetically over the other.
Genetic polymorphisms: Derivative trial protocols treated CYP2C9 genotype as a source of exposure variability and excluded participants on CYP2C9 inducers or inhibitors, making that genotype the most relevant to dose selection.
Sex differences: No human dosing difference has been established. The replicated rodent finding that only males gained lifespan, at matched blood levels, argues against assuming equivalent response across sexes.
Age: No age-adjusted regimen exists. Because hepatic and renal clearance both fall with age, published adult doses represent higher effective exposure in adults at the older end of the target range.
Baseline biomarkers: Liver chemistry drives eligibility rather than dose in published protocols, which required transaminases at or below three times the upper limit of normal and normal bilirubin before dosing.
Pre-existing conditions: Prior gastrointestinal surgery or disease altering absorption, cardiac conduction abnormalities and uncontrolled intercurrent illness were all exclusion criteria in the most recent oral protocol.

Discontinuation & Cycling

Not framed as lifelong: No protocol contemplates indefinite human use. Oncology dosing continued only until progression or toxicity, and dermatological use ran for a fixed 14-to-28-day course.
No documented withdrawal effects: Neither the trial reports nor the case literature describes rebound, dependence or discontinuation symptoms. Reported liver injury resolved over 1 to 17 weeks after intake stopped.
Tapering not applicable: Because no withdrawal syndrome exists, abrupt discontinuation is what the published record describes, and it is what every resolved case of chaparral-associated liver injury involved.
Cycling for organ recovery rather than efficacy: No tolerance to the compound has been documented, so cycling has no efficacy rationale. Interrupted courses are argued for instead on cumulative hepatic and renal exposure grounds.
Rodent dosing was continuous: The lifespan findings came from lifelong uninterrupted feeding from mid-life onward, so intermittent human schedules have no animal precedent for the longevity claim.

Sourcing and Quality

No pharmaceutical oral product exists: The topical cream left the market in 1996 and no oral prescription form was ever approved, so all human-accessible material is either a botanical product or a laboratory reagent.
Botanical products vary widely: Chaparral capsules, tinctures and teas are sold as dietary supplements without standardisation to lignan content, so two products bearing the same label can differ several-fold in delivered dose.
Reagent-grade material is not food-grade: Catalogue nordihydroguaiaretic acid is manufactured for laboratory use, is documented for chemical purity rather than for human safety, and carries no controls on residual solvents or heavy metals.
What to look for: Independent third-party verification through NSF International, USP or ConsumerLab, a stated lignan percentage, a botanical identity test confirming Larrea tridentata, and a batch certificate of analysis with a lot number.
Adulteration and identity risk: Desert botanicals are subject to species substitution, and the plant name shifts between chaparral, creosote bush and greasewood, so labelling alone does not confirm which species is in the container.
Compounding pharmacies: No compounding pharmacy supplies this as a finished preparation, since there is neither an approved product to replicate nor a pharmacopoeial monograph for an oral dosage form.

Practical Considerations

Time to effect: The topical trial assessed lesion counts one month after a 14-to-28-day course. Oral oncology dosing used three 28-day cycles before any interim assessment, so effects are not measured in days.
Common pitfall — treating a food antioxidant as a safe dose: The compound’s history as a preservative involved milligram-level dietary traces, not the gram-level daily oral doses used in trials, and the toxicity findings arose at the higher end.
Common pitfall — assuming the plant equals the molecule: Chaparral preparations deliver an uncontrolled mixture, and the liver injury reports involve the plant, not measured doses of the isolated compound.
Common pitfall — extrapolating male rodent lifespan data: The lifespan finding was sex-specific, dose-dependent and unaccompanied by evidence of better health, and an independent replication found more fatal tumours.
Regulatory status: The compound is not an approved drug in the United States; the topical form was withdrawn in 1996. Chaparral is sold as a dietary supplement under a 1992 Food and Drug Administration advisory on liver injury.
Cost and accessibility: Chaparral products are inexpensive and sold without prescription. Because no payer reimburses them and no competing reimbursable product exists, insurers and health systems have no financial incentive favouring or opposing their use.

Interaction with Foundational Habits

Sleep: No direct interaction is documented; the relationship is indirect. Neither stimulant nor sedative properties have been described, and no trial recorded sleep disturbance. The only relevant consideration is that severe liver injury presents with fatigue and malaise, which can be mistaken for poor sleep quality rather than recognised as an adverse event.
Nutrition: The interaction is direct and two-way. Hepatic clearance depends on glucuronidation, which draws on the same conjugation capacity that alcohol and high-dose acetaminophen consume, so alcohol intake competes directly with clearance. Fed and fasted administration produced comparable systemic exposure for the methylated derivative, so meal timing is not a lever on absorption.
Exercise: The interaction is potentially blunting but unproven in humans. Lipoxygenase and other eicosanoid signals participate in the inflammatory response that drives training adaptation, so a potent inhibitor could dampen it, as high-dose antioxidants do. No study has measured strength or endurance adaptation under this compound.
Stress management: No direct interaction with cortisol or the stress response has been described. The indirect consideration is that the required liver and kidney monitoring schedule, plus the interaction surface with common medications, imposes an administrative load, and irregular monitoring is the pathway by which a silent enzyme rise becomes a clinical event.

Monitoring Protocol & Defining Success

Baseline testing before any oral course establishes the reference values against which later change is judged, and it screens out the exclusion criteria used in published protocols. A full liver panel, kidney filtration markers with urinalysis, a complete blood count with clotting time, and fasting metabolic markers are drawn before the first dose, along with a medication review against the compound’s enzyme-inhibition profile.

Ongoing monitoring follows the onset window of the reported injuries: liver chemistry at 4 weeks, at 8 weeks, then every 3 months while intake continues; kidney markers and urinalysis every 6 months; metabolic and inflammatory markers every 6 to 12 months. Kidney imaging becomes relevant beyond a year, since cysts are the rodent lesion. Success means claimed markers moving while liver and kidney markers hold at baseline; a rising transaminase in isolation counts as failure regardless of any other gain.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT	Men 10–26 U/L; women 8–22 U/L	Primary signal of liver-cell injury	Conventional labs flag only above roughly 40–55 U/L, so a doubling within range is missed by standard reporting; fasting not required
AST	10–26 U/L	Confirms hepatocellular pattern alongside ALT	AST is aspartate aminotransferase, a second liver enzyme; conventional labs flag only above roughly 40 U/L; it also rises after intense exercise, so a specimen drawn within 48 hours of hard training reads high
ALP	40–90 U/L	Detects the cholestatic pattern typical of chaparral injury	ALP is alkaline phosphatase, raised when bile flow is impeded; the conventional range runs to roughly 120 U/L; bone disease also raises it, so a paired gamma-glutamyl transferase localises the source
GGT	Men below 25 U/L; women below 20 U/L	Confirms a biliary source and flags glutathione turnover	GGT is gamma-glutamyl transferase; conventional upper limits are far higher, roughly 55 U/L in men and 38 U/L in women; alcohol raises it independently, which is one reason abstinence simplifies interpretation
Total bilirubin	0.3–1.0 mg/dL	Jaundice was the presenting sign in reported cases	Any rise alongside raised transaminases marks a more severe injury; Gilbert’s syndrome causes benign isolated elevation
Creatinine with eGFR	eGFR above 90 mL/min/1.73 m²	Tracks the filtration function the rodent lesion destroys	eGFR is estimated glomerular filtration rate, calculated from creatinine; conventional reporting treats anything above 60 mL/min/1.73 m² as normal, so early decline is invisible there; high muscle mass lowers the estimate spuriously
Cystatin C	0.6–0.9 mg/L	Filtration marker independent of muscle mass	Conventional laboratory ranges extend to roughly 1.0–1.1 mg/L; most informative alongside creatinine when the two disagree; not affected by fasting or meat intake
Urinalysis (protein and blood)	Negative for both	Detects tubular injury before filtration falls	A first-morning specimen is the most concentrated; a positive result is the point at which the published record turns to imaging rather than continued dosing
Platelet count with INR	Platelets 150–400 ×10⁹/L; INR 0.9–1.1	Covers the bleeding signal seen in long-term rodent dosing and liver synthetic function	INR is the international normalised ratio, a standardised measure of clotting time; it also rises as liver function fails
Fasting triglycerides	Below 100 mg/dL	Tests the rodent metabolic claim directly	The conventional cut-off is 150 mg/dL, so a 120 mg/dL result reads normal on a standard report; requires a 12-hour fast; alcohol within 72 hours inflates the result
Fasting glucose with HbA1c	Glucose 75–86 mg/dL; HbA1c 4.8–5.4%	Second axis of the claimed metabolic effect	Conventional ranges are wider, glucose 70–99 mg/dL and HbA1c below 5.7%; HbA1c is glycated haemoglobin, reflecting average glucose over about three months; anaemia distorts it
hs-CRP	Below 0.5 mg/L	Tracks the anti-inflammatory claim	hs-CRP is high-sensitivity C-reactive protein, a general marker of inflammation; conventional cardiovascular reporting calls anything below 3.0 mg/L unremarkable; any recent infection or injury invalidates the reading for about two weeks

Qualitative markers worth tracking alongside the laboratory panel:

Appetite loss, nausea or right-sided abdominal discomfort, which preceded jaundice in reported liver injury cases
Darkened urine or pale stools, which indicate impaired bile flow before yellowing of skin or eyes appears
Unusual fatigue disproportionate to sleep and training load
Easy bruising or prolonged bleeding from minor cuts
For topical use, escalating redness, itching or spreading rash beyond the treated area, distinguishing allergy from expected irritation
Cognitive clarity, given the single reported instance of cognitive disturbance at gram-level oral dosing

Emerging Research

Oral exposure ceiling in brain tumours: A phase 1 dose-escalation trial of the methylated derivative in 20 adults with recurrent high-grade glioma found doses from 1,200 to 6,000 mg daily tolerable but systemic exposure flat across doses (NCT02575794; Ahluwalia et al., 2024).
No active trials: A ClinicalTrials.gov search on 2026-09-10 returned nine registered studies of the compound or its derivatives, all completed or terminated. None is recruiting, so near-term human data will come from re-analysis rather than new enrolment.
Terminated prostate programme: The phase 2 study of oral dosing in non-metastatic recurrent prostate cancer closed after 12 of a planned larger cohort, stopped at a preplanned interim analysis for absence of tumour-marker declines (NCT00678015).
Earlier glioma work: A phase 1/2 study of the same derivative in 35 adults with recurrent high-grade glioma completed in 2009 and set the precedent for the intravenous-to-oral switch tested later (NCT00404248).
Analogues designed to drop the toxicity: Synthetic analogues lowered triglycerides in dyslipidaemic rats, testing whether the metabolic effect survives removal of the reactive catechol that is blamed for organ injury (Singh et al., 2019).
Fatty liver models: Work in a mouse model of non-alcoholic steatohepatitis (fatty liver with inflammation and scarring) reported reduced molecular and histological damage, an area where a human trial would decide whether the rodent metabolic signal transfers (Han et al., 2019).
Evidence that weakens the case — invertebrate replication: A multi-site nematode programme found lifespan effects that depended on species, strain and assay method, uncoupling lifespan from health measures and undercutting claims of a conserved pathway (Banse et al., 2024).
Evidence that weakens the case — rodent tumour signal: An independent study in one inbred-hybrid mouse strain reproduced lifespan extension while reporting more fatal liver, lung and thymus tumours and abdominal bleeding — absent from federal testing, which used genetically heterogeneous mice (Spindler et al., 2015).
Mechanistic direction to watch: Identification of the compound as a p300 inhibitor that triggers autophagy gives a testable non-antioxidant explanation for the rodent lifespan effect and a route to compounds without the catechol (Tezil et al., 2019).

Conclusion

Nordihydroguaiaretic acid is a desert-plant antioxidant with an unusually long and mixed record: a food preservative for two decades, a herbal tea sold for cancer, a prescription topical cream, and now a compound that lengthened the lives of male mice in a government animal programme.

For readers optimising their own healthspan, the gap between those two roles matters. The only benefit in humans that rests on a controlled trial is clearance of sun-damaged skin patches by the cream, a product no longer sold. Oral use has been tested once in a small cancer study that stopped early. Everything said about lifespan, blood fats, blood sugar, inflammation or nerve protection comes from animals or cells.

The safety record runs in the opposite direction, and it is the stronger body of evidence. Prolonged intake of the parent plant has caused liver injury severe enough to require transplantation, rats develop kidney cysts reliably, and one person developed kidney disease and cancer after years of the tea. The compound also interferes with several enzymes that clear common medications.

The evidence base is thin and partly conflicted. Company-funded work has concentrated on modified versions, and the herbal trade group that organised the 1992 withdrawal represents sellers of the products in question. What survives that scrutiny is a molecule whose animal longevity signal is real and whose human safety signal is worse.

Top - Benefits - Risks - Protocol

Nordihydroguaiaretic Acid for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Clearance of Actinic Keratoses with the Topical Form

Low 🟩

Slowed Rise of Prostate-Specific Antigen in Recurrent Prostate Cancer

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

Lower Blood Triglycerides and Liver Fat

Lowered Blood Glucose in Rodent Models of Type 2 Diabetes

Damped Leukotriene-Driven Inflammation

Neuroprotection in an Animal Model of Motor Neurone Disease

Antiviral and Antimicrobial Activity in Laboratory Assays

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Drug-Induced Liver Injury

Contact Dermatitis and Local Irritation from the Topical Form

Gastrointestinal and Neurologic Adverse Events at Gram-Level Oral Doses

Low 🟥

Cystic Kidney Disease

Speculative 🟨

Increased Tumour Burden and Bleeding ⚠️ Conflicted

Reactive Quinone Formation

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion